Research progress of therapeutic vaccines for treating chronic hepatitis B

Hepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma. 1 Despite the availability of prophylactic vaccines against hepatitis B for over 3 decade...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2017-05, Vol.13 (5), p.986-997
Main Authors: Li, Jianqiang, Bao, Mengru, Ge, Jun, Ren, Sulin, Zhou, Tong, Qi, Fengchun, Pu, Xiuying, Dou, Jia
Format: Article
Language:English
Subjects:
chronic hepatitis B
Clinical Trials as Topic
Drug Discovery
Hepatitis B - therapy
Hepatitis B Surface Antigens - chemistry
Hepatitis B Surface Antigens - immunology
Hepatitis B Vaccines - chemistry
Hepatitis B Vaccines - classification
Hepatitis B Vaccines - therapeutic use
Hepatitis B virus
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - therapy
Humans
Review
therapeutic vaccine
Vaccines, DNA - administration & dosage
Vaccines, DNA - therapeutic use
Vaccines, Subunit - administration & dosage
Vaccines, Subunit - therapeutic use
Virus Replication - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma. 1 Despite the availability of prophylactic vaccines against hepatitis B for over 3 decades, there are still more than 2 billion people have been infected and 240 million of them were chronic. Antiviral therapies currently used in the treatment of CHB (chronic hepatitis B) infection include peg-interferon, standard α-interferon and nucleos/tide analogs (NAs), but none of them can provide sustained control of viral replication. As an alternative strategy, therapeutic vaccines for CHB patients have been widely studied and showed some promising efficacies in dozens of preclinical and clinical trials. In this article, we review current research progress in several types of therapeutic vaccines for CHB treatment, including protein-based vaccines, DNA-based vaccines, live vector-based vaccines, peptide-based vaccines and cell-based therapies. These researches may provide some clues for developing new treatments in CHB infection.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2016.1276125